October 16, 2019
Webinar
The FDA’s Orange Book plays a critical role in pharmaceutical patent litigation under the Hatch-Waxman Act. The Orange Book lists approved drug products, as well as patents and regulatory exclusivities relating to those products. When a drug company files a 505(b)(2) application or abbreviated new drug application (ANDA) seeking approval for a proposed drug product, it must certify as to each patent listed in the Orange Book for the reference listed drug. If the company files a paragraph IV certification, alleging that a listed patent is invalid or will not be infringed by the proposed drug product, the patent owner can sue the company for patent infringement. Filing suit within 45 days of a paragraph IV notice generally entitles the patent owner to a regulatory stay, where the 505(b)(2) or ANDA cannot be approved for a period of 30 months while the patent infringement litigation plays out.
As the law continues to develop through Hatch-Waxman litigations, the FDA is taking steps to “enhance” the “important resource” that is the Orange Book.
Please join us as we discuss recent developments relating to Hatch-Waxman litigation and the FDA’s Orange Book, including:
Speakers:
Shana K. Cyr, Ph.D.
Mark J. Feldstein
Ryan P. O’Quinn, Ph.D.
Moderator:
Drew D. Christie
Date:
Wednesday, October 16, 2019
Time:
10:00 a.m. PDT
1:00 p.m. EDT
7:00 p.m. CEST
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.